Skip to content
Screener

Arvinas ARVN Q2 2026 earnings

Reported August 4, 2026 · Before market open

Revenue$249.7MBeat by $189.0M
EPS$2.58Beat by $2.95
Revenue estimate$60.7M
EPS estimate-$0.37
“The approval of VEPPANU, the first ever for a PROTAC degrader, was a significant achievement for the Company, and our subsequent licensing of VEPPANU to Rigel Pharmaceuticals promises to unlock its commercial potential and provide access to patients as efficiently as possible.”
Randy Teel

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$17.4M
EPS estimate-$0.85

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$609.4M+2.7%
Enterprise value$530.7M+8.7%
P/S6.8×+5.2×

FAQ

When did Arvinas report Q2 2026 earnings?
Arvinas (ARVN) reported Q2 2026 earnings on August 4, 2026 before market open.
What were Arvinas's Q2 2026 revenue and EPS?
Arvinas reported revenue of $249.7M and eps of $2.58 for Q2 2026.
Did Arvinas beat estimates in Q2 2026?
Revenue beat the consensus estimate of $60.7M by $189.0M. EPS beat the consensus estimate of $-0.37 by $2.95.
How did Arvinas's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1014.7% from $22.4M a year earlier.
Where can I find Arvinas's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-052139) and the 10-Q periodic report (0001628280-26-052554) directly on SEC EDGAR. The filing index links above go to sec.gov.